Bon Jovi enlists in Advil's battle with Tylenol

Share this article:
Bon Jovi enlists in Advil's battle with Tylenol
Bon Jovi enlists in Advil's battle with Tylenol
Jon Bon Jovi is the latest celebrity pitchman for Pfizer Consumer Healthcare's Advil.

The ‘80s hard rocker, now entering his fifties, cut a 30-second testimonial for Pfizer's OTC painkiller, quipping “pain does not have much of a place in my life. I checked the schedule and it's not on it.” Bon Jovi, it seems, became an Advil loyalist after he injured his calf muscle onstage in New Jersey last year. Additional digital content from the taping is up on TakeAdvil.com, which also features testimonials from Regis and Joy Philbin, along with a host of non-famous people, as well as content touting the Jon Bon Jovi Soul Foundation.  

The campaign, which launched last year with TV, print and web ads, takes direct aim at J&J's rival Tylenol, with spots opening with a narrator saying: “Every day, thousands of people are switching from Tylenol to Advil.”

“Our Advil Stories campaign emphasizes that everyone experiences physicial pain for some reason in their lives, no matter who they are,” said Srini Sripada, senior director, pain management for Pfizer Consumer Healthcare, in a statement. “We know that Advil consumers are our greatest ambassadors and that pain is something we all share.”
Share this article:

Email Newsletters

More in News

Five things for pharma marketers to know: Thursday, August 21

Five things for pharma marketers to know: Thursday, ...

An Ebola survivor is set to leave Emory University Hospital, but the cause of the cure is uncertain, the FDA has approved a new type 1 diabetes test, and the ...

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Gaucher disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.